Theramex has announced that its entire FemSeven portfolio of products will return to pharmacy shelves by mid-2021.
As of now, FemSeven Conti, one of the FemSeven portfolio of products, is available from Alliance Healthcare.
Earlier, non-patient-safety related quality issues were reported in the gradual withdrawal of the FemSeven portfolio from the market.
The company said in its latest update: “Theramex holds the marketing authorisation for FemSeven 50, 75 and 100 (estradiol), FemSeven Conti (estradiol/levonorgestrel) and FemSeven Sequi (estradiol/levonorgestrel) in the UK and Europe since acquiring these products from Teva Pharmaceuticals Ltd on February 1, 2018.
“…We have since been working diligently to fix these issues and are pleased confirm that the entire FemSeven® portfolio of products will be returning in 2021 commencing with FemSeven Conti® which is available now from Alliance Healthcare.”